- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Biliary Tract Neoplasms, Biliary Duct Obstruction, Unresectable Pancreatic Cancer, Periampullary Cancer, Periampullary Carcinoma Non-Resectable
- Interventions
- Endoscopic Ultrasound Guided Biliary Drainage, ERCP
- Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
- Interventions
- Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 441
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 325 more
- Conditions
- Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Interventions
- 4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Nelfinavir Mesylate, Oregovomab, Stereotactic Body Radiation Therapy, Therapeutic Conventional Surgery
- Procedure · Drug · Other + 2 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases, Prostate Cancer, Liver Metastases, Oligoprogressive Nodal Metastases, Metachronous Nodal Metastases, Synchronous Nodal Metastases, Mesothelioma, Spine Metastases, Brain Metastases, Borderline Resectable Pancreatic Carcinoma
- Interventions
- MR-guided Linac
- Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreatic Cancer
- Interventions
- genistein
- Dietary Supplement
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pancreatic Cancer
- Interventions
- Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine, Stereotactic Body Radiation (SBRT)
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Milwaukee, Wisconsin
- Conditions
- Pancreatic Cancer
- Interventions
- TTI-101, Stereotactic body radiation therapy
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • St Louis, Missouri
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7
- Interventions
- Capecitabine, Laboratory Biomarker Analysis, Nab-paclitaxel, Questionnaire Administration, Radiation Therapy
- Drug · Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 5
- States / cities
- Houston, Texas • League City, Texas • Sugar Land, Texas + 1 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- ASP2138, Oxaliplatin, Leucovorin, 5-FU, Irinotecan, Gemcitabine, Nab-paclitaxel, Capecitabine
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Durham, North Carolina
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage III Colorectal Cancer, Stage III Gastric Cancer, Stage III Pancreatic Cancer, Unresectable Digestive System Adenocarcinoma, Unresectable Pancreatic Carcinoma
- Interventions
- Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
- Interventions
- Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein
- Drug · Other · Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Newport Beach, California
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- PTP-01
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Adenocarcinoma of Pancreas
- Interventions
- Irinotecan, Oxaliplatin, Leucovorin, 5-FU
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7
- Interventions
- Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nab-paclitaxel, Paricalcitol, Pembrolizumab, Therapeutic Conventional Surgery
- Drug · Other · Biological + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pancreatic Cancer
- Interventions
- Multi-Modality; IORT, Surgery, Radiation, Chemotherapy
- Other
- Lead sponsor
- Southwestern Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Lung Carcinoid Tumor, Malignant Pancreatic Gastrinoma, Malignant Pancreatic Glucagonoma, Malignant Pancreatic Insulinoma, Malignant Pancreatic Somatostatinoma, Metastatic Digestive System Neuroendocrine Tumor G1, Ovarian Carcinosarcoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Beta Cell Adenoma, Pancreatic Delta Cell Adenoma, Pancreatic G-Cell Adenoma, Pancreatic Polypeptide Tumor, Recurrent Adult Liver Carcinoma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIA Uterine Corpus Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIC Uterine Corpus Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer, Uterine Carcinosarcoma
- Interventions
- Bevacizumab, Temsirolimus
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 57
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 44 more
- Conditions
- Pancreatic Cancer
- Interventions
- Biopsy, FOLFIRINOX, Ciprofloxacin, Metronidazole, Pembrolizumab, Surgical Resection
- Procedure · Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Cancer
- Interventions
- Stereotactic Body Radiation Therapy
- Radiation
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Pancreatic Cancer
- Interventions
- Daily Adaptive External Beam Radiation Therapy
- Radiation
- Lead sponsor
- Varian, a Siemens Healthineers Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • St Louis, Missouri • Cleveland, Ohio
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Cisplatin, Computed Tomography, Durvalumab, Fluorouracil, Gemcitabine, Irinotecan, Leucovorin, Ligritinib, Magnetic Resonance Imaging, Oxaliplatin, Zimberelimab
- Procedure · Drug · Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Interventions
- Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Irinotecan Hydrochloride, Leucovorin Calcium, Oxaliplatin
- Drug · Radiation
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Pancreas Cancer, Cancer
- Interventions
- CivaSheet
- Device
- Lead sponsor
- CivaTech Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Pancreatic Adenocarcinoma Non-resectable
- Interventions
- ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003)
- Combination Product
- Lead sponsor
- Continuity Biosciences, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Morgantown, West Virginia
- Conditions
- Pancreatic Cancer
- Interventions
- dexamethasone, fluorouracil, brachytherapy, phosphorus P32, radiation therapy
- Drug · Radiation
- Lead sponsor
- Center for Molecular Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2007
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Garden City, New York